![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C11H16N2O2 |
Molar mass | 208.261 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Aloracetam ( INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds. [1] [2] [3] It was studied by Aventis for the treatment of Alzheimer's disease, [4] but was never marketed.
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C11H16N2O2 |
Molar mass | 208.261 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Aloracetam ( INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds. [1] [2] [3] It was studied by Aventis for the treatment of Alzheimer's disease, [4] but was never marketed.